# US 2012/0251548 A1 · Treatment of Dermatological Pathologies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251548 A1
- Document ID: US20120251548A1
- Status: Published application
- Kind: A1
- Application number: 13/437,159
- Filed: 2012-04-02
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Assignees: Xbiotech, Inc.
- Inventors: John Simard
- Web page: https://patentgrep.com/patent/US20120251548A1

## CPC

- C07K 16/245: {IL-1}
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/244: {Interleukins [IL]}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Skin inflammation in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.

## Claims

### Claim 1

A method of reducing skin inflammation in a human subject, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an agent that selectively binds IL-1α effective to reduce skin inflammation in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent is an anti-IL-1α antibody.

### Claim 3 (depends on 2)

The method of claim 2, wherein the anti-IL-1α antibody is a monoclonal antibody.

### Claim 4 (depends on 3)

The method of claim 3, wherein the monoclonal antibody is an IgG1.

### Claim 5 (depends on 3)

The method of claim 3, wherein the monoclonal antibody comprises a complementarity determining region of MABp1.

### Claim 6 (depends on 3)

The method of claim 3, wherein the monoclonal antibody is MABp1.

### Claim 7 (depends on 1)

The method of claim 1, wherein the skin inflammation is associated with acne vulgaris.

### Claim 8 (depends on 1)

The method of claim 1, wherein the skin inflammation is associated with psoriasis vulgaris.
